"10.1371_journal.pone.0149289","plos one","2016-02-22T00:00:00Z","Kaatje Bollaerts; Vivek Shinde; GaÃ«l Dos Santos; Germano Ferreira; Vincent Bauchau; Catherine Cohet; Thomas Verstraeten","P95 Pharmacovigilance and Epidemiology Services, Koning Leopold III Laan 1, 3001 Leuven, Belgium; GSK Vaccines, 2301 Renaissance Boulevard, King of Prussia, PA 19406, United States of America; Business & Decision Life Sciences (contractor for GSK Vaccines), Rue Saint Lambert 141, 1200 Brussels, Belgium; GSK Vaccines, Avenue Fleming 20, B-1300 Wavre, Belgium","Conceived and designed the experiments: KB VS GDS GF VB CC TV. Performed the experiments: KB. Analyzed the data: KB. Wrote the paper: KB VS GDS GF VB CC TV.","KB, TV received consulting fees from GSK for the conduct of this study. At the time the work was performed, VB, CC, GF, VS were employees at GSK. VB, CC and VS hold stock options/restricted shares from the company. GDS is a full-time consultant on behalf of a GSK group of companies. This does not change the authors' adherence to all PLOS ONE policies.on sharing data and materials.","2016","02","Kaatje Bollaerts","KB",7,TRUE,7,1,1,7,TRUE,TRUE,FALSE,0,NA,FALSE
